Abstract: This invention relates to a lubricating oil composition comprising or resulting from the admixing of: a) 50 to 99 mass % of one or more base oils; b) 0.1 to 15 mass % of one or more functionalized olefin copolymer having an Mn of from 10,000 to 35,000 g/mol; c) 0.1 to 20 mass % of one or more detergents wherein the detergent comprises at least one calcium detergent having a TBN of more than 100 mg KOH/g; at least one calcium detergent having a TBN of 100 mg KOH/g or less; and at least one magnesium detergent, where the difference in the TBN's for the Ca detergents is at least 100 mg KOH/g; d) 0.01 to 40 mass % of one or more dispersants wherein the dispersants comprise at least one borated dispersant and at least one non borated dispersant; e) 0.01 to 20 of mass % sulfurized fatty acid ester; f) 0.01 to 5 mass % of one or more amine or phenol based antioxidants; and g) 0.001 to 15 mass % of molybdenum containing compound, where the lubricating oil composition has: 1) a sulfated ash content of 0.

Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.

Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.

Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.

Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.

Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.

Abstract: A method and device for managing akinetic episodes of "freezing" and "start hesitation" experienced by individuals who suffer from Parkinson's disease and related disorders of the extrapyramidal nervous system projects a beam of light to facilitate mobility. The projection device, used alone or adapted to an assistive support such as a cane or walker, or to an item of clothing, projects a thin beam or discrete pattern of light using a laser, flash or other high-intensity light source to provide a luminous mark in the path of a standing individual. The mark is flashed at will by push-button control, and provides a visual cue to the operator encouraging him or her to step up and over the projected image. This cue breaks the freeze and permits the user to resume motion. Preferably a timer extinguishes the light after a brief interval. Circuitry may blink the light during the projection interval to enhance its efficacy.